Chinese glucose monitor maker Sinocare (SZ:300298) and a sovereign wealth fund there are said to be in the hunt for the diabetes business Johnson & Johnson (NYSE:JNJ) is looking to unload. The New Brunswick, N.J.-based healthcare conglomerate early last year announced a strategic review of its LifeScan, Animas and Calibra Medical diabetes businesses and later elected to […]
johnsonandjohnson
Metavention raises $65m to tackle diabetes with metabolic neuromodulation therapy
Metavention said today that it closed a $65 million Series C round with funding from New Enterprise Associates, Sanderling Ventures and others. The medical device maker plans to use the funds to optimize its transcatheter-based metabolic neuromodulation therapy for people with Type II diabetes and prepare it for a Phase II trial in the U.S. […]
United Therapeutics dishes out $210m to settle charity-kickback claims
United Therapeutics (NSDQ:UTHR) has agreed to pay $210 million to squash claims that it used a charity to illegally cover Medicare patients’ out-of-pocket costs in an attempt to boost sales. Drug companies are not allowed to subsidize co-pays for people enrolled in Medicare, but they can donate to independent non-profits that provide co-pay assistance. The settlement […]
Tandem looks to get in on ex-Animas customer base
Tandem Diabetes Care (NSDQ:TNDM) and Dexcom (NSDQ:DXCM) announced yesterday that the companies would extend their existing joint welcome program aimed at luring Animas customers as Johnson & Johnson (NYSE:JNJ) bails out of the insulin pump biz. Tandem and Dexcom’s t:slim X2 welcome program was slated to end on Dec. 31, but the companies said yesterday that it would continue until […]
J&J’s LifeScan touts studies of OneTouch blood glucose monitoring system
Two recently-published studies of LifeScan‘s OneTouch Verio Flex blood glucose monitoring system showed that the technology is accurate, reliable and linked with improvements in glycemic control, the Johnson & Johnson (NYSE:JNJ) business touted today. The release comes just days after the healthcare giant revealed that it plans to shut down its Animas insulin pump business and review […]
The 11 most innovative medical devices of 2017
The nominees for the best medical technology of 2017 were recently announced for the 11th Annual Prix Galien USA Awards. The Galien Foundation, the host of the awards, hands out the Prix Galien Award annually to examples of outstanding biomedical and technology product achievement designed to improve human condition. Before candidates can qualify for the […]
Johnson & Johnson pharma revenue continues to climb in Q3
Johnson & Johnson‘s (NYSE:JNJ) third quarter profits were down by -12%, the company reported today, but revenue topped expectations and the healthcare giant singled out its pharmaceutical business as a driving factor. “Johnson & Johnson accelerated growth in the third quarter. This is driven by the strong performance of our pharmaceutical business, and augmented by […]
Insulet looks to lure Animas users
Just days after Johnson & Johnson (NYSE:JNJ) revealed that it plans to shut down its 410-worker Animas insulin pump subsidiary, Insulet (NSDQ:PODD) said it would offer existing Animas insulin pump users a free trial of the company’s Omnipod system. Insulet’s Welcome Program includes a free Omnipod tubeless insulin delivery system, built-in blood glucose meter and 30 days […]
Johnson & Johnson to shutter Animas insulin pump biz
Johnson & Johnson (NYSE:JNJ) said today that it plans to shut down its 410-worker Animas insulin pump subsidiary, offering to help some 90,000 Animas patients transfer to products made by rival Medtronic (NYSE:MDT). The Chesterbrook, Pa.-based company said it will stop making its Animas Vibe and OneTouch Ping pumps, but will continue to provide customer […]
J&J’s Janssen wins $45m BARDA contract for Ebola vaccine dev
Johnson & Johnson (NYSE:JNJ) said today that its Janssen Pharmaceutical subsidiary Janssen Vaccines & Prevention B.V received a $44.7 million award and collaborative partnership from the US Biomedical Advanced Research and Development Authority to support its development of an investigational Ebola vaccine regimen. The deal comes with an option for BARDA to provide additional funding over 5 […]
